Abstract
Metabolomics is a recently emerging member of the “omics” technologies. It aims at detecting and quantifying all detectable small molecules, the so-called metabolites, present in a biological sample. Because of the lower number of metabolites compared with the number of genes and proteins identified in genomics and proteomics approaches, data of metabolic studies are less complex and may therefore be more informative. Metabolomics may thus significantly contribute to our understanding of disease mechanisms. Autoimmune diseases are of growing clinical relevance, and due to the chronic nature of these diseases successful treatment is often challenging. In the past years, a variety of studies have been published about the metabolome of autoimmune diseases such as Crohn ’ s disease and rheumatoid arthritis. However, our understanding of the role of different metabolites in the pathogenesis of autoimmune diseases is still far from being complete.
Keywords: Autoimmunity, Crohn's disease, rheumatoid arthritis, metabolomics
Current Drug Discovery Technologies
Title: Metabolic Changes in Autoimmune Diseases
Volume: 6 Issue: 4
Author(s): Karsten Seeger
Affiliation:
Keywords: Autoimmunity, Crohn's disease, rheumatoid arthritis, metabolomics
Abstract: Metabolomics is a recently emerging member of the “omics” technologies. It aims at detecting and quantifying all detectable small molecules, the so-called metabolites, present in a biological sample. Because of the lower number of metabolites compared with the number of genes and proteins identified in genomics and proteomics approaches, data of metabolic studies are less complex and may therefore be more informative. Metabolomics may thus significantly contribute to our understanding of disease mechanisms. Autoimmune diseases are of growing clinical relevance, and due to the chronic nature of these diseases successful treatment is often challenging. In the past years, a variety of studies have been published about the metabolome of autoimmune diseases such as Crohn ’ s disease and rheumatoid arthritis. However, our understanding of the role of different metabolites in the pathogenesis of autoimmune diseases is still far from being complete.
Export Options
About this article
Cite this article as:
Seeger Karsten, Metabolic Changes in Autoimmune Diseases, Current Drug Discovery Technologies 2009; 6 (4) . https://dx.doi.org/10.2174/157016309789869074
DOI https://dx.doi.org/10.2174/157016309789869074 |
Print ISSN 1570-1638 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6220 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Dendritic Cells in Autoimmune Liver Diseases
Current Immunology Reviews (Discontinued) Circulating Matrix Metalloproteinase-9 Levels in Patients with Systemic Lupus Erythematosus: A Meta-analysis
Current Pharmaceutical Design Chlorogenic Acid Suppresses a Cell Adhesion Molecule in Experimental Autoimmune Myocarditis in Mice
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Lipid-Based Nanocarriers for RNA Delivery
Current Pharmaceutical Design Development and Chemistry of Histamine H4 Receptor Ligands as Potential Modulators of Inflammatory and Allergic Responses
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Immune-Regulatory Mechanisms of Classical and Experimental Multiple Sclerosis Drugs: A Special Focus on Helminth-Derived Treatments
Current Medicinal Chemistry Gut Inflammation: Current Update on Pathophysiology, Molecular Mechanism and Pharmacological Treatment Modalities
Current Pharmaceutical Design Novel Carriers for Coenzyme Q10 Delivery
Current Drug Delivery Comparative Biochemistry of GH3, GH20 and GH84 β-N-acetyl-Dhexosaminidases and Recent Progress in Selective Inhibitor Discovery
Current Drug Targets Current and Future Therapies Targeting the Immune System in Multiple Sclerosis
Current Pharmaceutical Biotechnology Nano-formulations for Diagnostics and Therapeutics of Foot-and-Mouth Disease in Animals
Nanoscience & Nanotechnology-Asia Editorial [Hot Topic: Toll-Like Receptors and Innate Immunity: Potential Drug Targets for Treatment of Infectious, Inflammatory, and Autoimmune Diseases (Executive Editor: Emilio Jirillo)]
Current Pharmaceutical Design A New Drug Candidate (GEMSP) for Multiple Sclerosis
Current Medicinal Chemistry Role of C1858T Polymorphism of Lymphoid Tyrosine Phosphatase in Egyptian Children and Adolescents with Type 1 Diabetes
Current Diabetes Reviews The Roles of MicroRNAs in Atherosclerosis
Current Medicinal Chemistry Acquired Hemophilia as Initial Presentation in a Patient with Systemic Lupus Erythematosus
Current Rheumatology Reviews Statins Therapy for Connective Tissue Diseases: New Therapeutic Opportunities
Endocrine, Metabolic & Immune Disorders - Drug Targets Kynurenine System and Multiple Sclerosis, Pathomechanism and Drug Targets with An Emphasis on Laquinimod
Current Drug Targets Alopecia Areata
Recent Patents on Inflammation & Allergy Drug Discovery Novel Superactive Leptin Antagonists and their Potential Therapeutic Applications
Current Pharmaceutical Design